Patents

Five things for pharma marketers to know: Tuesday, September 19, 2017

Five things for pharma marketers to know: Tuesday, September 19, 2017

By

Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women's health portfolio; the FDA approves GSK's COPD combo

Five things for pharma marketers to know: Monday, September 11, 2017

Five things for pharma marketers to know: Monday, September 11, 2017

By

Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

By

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

Five things for pharma marketers to know: Thursday, February 9, 2017

Five things for pharma marketers to know: Thursday, February 9, 2017

By

Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws

Five things for pharma marketers to know: Tuesday, January 17, 2017

Five things for pharma marketers to know: Tuesday, January 17, 2017

By

Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal

Five things for pharma marketers to know: Friday, January 6, 2017

Five things for pharma marketers to know: Friday, January 6, 2017

By

Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending

Five things for pharma marketers to know: Tuesday, September 20, 2016

Five things for pharma marketers to know: Tuesday, September 20, 2016

By

GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

By

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

By

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

By

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

By

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

By

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Five things for pharma marketers to know: Friday, March 25, 2016

Five things for pharma marketers to know: Friday, March 25, 2016

By

Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance

Five things for pharma marketers to know: Tuesday, August 25

Five things for pharma marketers to know: Tuesday, August 25

By

US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Five things for pharma marketers to know: Monday, June 1

Five things for pharma marketers to know: Monday, June 1

By

Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

By

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

By

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

Pfizer's Hospira deal shores up established product division

Pfizer's Hospira deal shores up established product division

By

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

By

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

New exclusivity rules confound

A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.

NY sues over Forest Alzheimer's medication

NY's attorney general alleges that a formulation switch is an attempt to create monopoly.

J&J, Vivus patent suit ends

J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.

Eisai sues FDA for more patent life

The Japanese drugmaker is looking to add as much as a year onto the patent life of some of its drugs after the DEA dragged out their scheduling decisions.